Sendai, Japan – May 20, 2025
RevolKa Ltd., a fast-growing biotechnology company leveraging AI for protein engineering, has announced the successful completion of a 210 million JPY (approximately $1.4 million USD) Series A extension funding round. The investment will fuel RevolKa’s therapeutic programs for rare diseases and enhance its AI-powered technology platform, aiProtein®.
This round was co-led by existing investors D3 LLC and TOHOKU University Venture Partners Co., Ltd., with participation from DEEPCORE Inc. The funding will support the company’s internal drug development initiatives and external partnership opportunities in the global biotech landscape.
Advancing the Future of Protein Engineering
RevolKa’s proprietary aiProtein® platform enables the design of high-performance therapeutic proteins by predicting and engineering specific biological functions. This approach is positioned to transform how drugs are discovered and optimized, particularly in areas where conventional protein design faces limitations.
A Strategic Step Toward Global Impact
With growing demand for innovative biologics in rare and complex diseases, this new capital enables RevolKa to expand its scientific reach and commercial potential. The aiProtein® platform is already being utilized in successful collaborations, and its unique sequence-to-function approach complements advances like AlphaFold, helping to bridge critical gaps in AI-driven molecular biology.
About RevolKa Ltd.
Founded in 2021 and based in Sendai, Japan, RevolKa is driven by the mission to improve human well-being through AI-based protein innovation. Its team of scientific experts and technology leaders is dedicated to developing new therapeutic solutions and industrial protein applications through its proprietary platform.
By